| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1535-6108(03)00022-9 |
| P698 | PubMed publication ID | 12620402 |
| P50 | author | Pier Paolo Pandolfi | Q7191735 |
| P2093 | author name string | Lloyd C Trotman | |
| P2860 | cites work | Mutation and cancer: statistical study of retinoblastoma | Q24618185 |
| Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms | Q28181035 | ||
| Regulation of PTEN transcription by p53 | Q28646911 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus | Q33944754 | ||
| Parc: a cytoplasmic anchor for p53. | Q34170344 | ||
| p53: good cop/bad cop. | Q34768712 | ||
| PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy | Q40765673 | ||
| HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation | Q40767550 | ||
| Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas | Q57591220 | ||
| Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse | Q73435294 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 97-99 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | PTEN and p53: who will get the upper hand? | |
| P478 | volume | 3 |
| Q30417988 | A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy |
| Q40184782 | A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth |
| Q48363650 | Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors |
| Q47349130 | BRAF alterations are associated with complex mutational profiles in malignant melanoma |
| Q37399899 | Beyond chemotherapy: targeted therapies in ovarian cancer |
| Q90153969 | Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways |
| Q24681977 | Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis |
| Q36071638 | Current progress of siRNA/shRNA therapeutics in clinical trials |
| Q37339357 | Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas) |
| Q91723445 | Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma |
| Q41899812 | High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function |
| Q38056288 | Inhibition of the IL-6 signaling pathway: A strategy to combat chronic inflammatory diseases and cancer |
| Q53748323 | Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q34734104 | Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk |
| Q33561350 | Involvement of miR-605 and miR-34a in the DNA damage response promotes apoptosis induction. |
| Q41897763 | Lloyd Trotman: of mice and men, cancer, and PTEN. Interviewed by Caitlin Sedwick |
| Q41553688 | MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas |
| Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
| Q27001260 | Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer |
| Q50027068 | MicroRNA-203 inhibits long noncoding RNA HOTAIR and regulates tumorigenesis through epithelial-to-mesenchymal transition pathway in renal cell carcinoma. |
| Q37861191 | NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia |
| Q37708804 | Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer |
| Q33406279 | Oscillations of the p53-Akt network: implications on cell survival and death |
| Q24563328 | PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase |
| Q30416701 | PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations |
| Q104795065 | Prostate apoptosis response-4 and tumor suppression: it's not just about apoptosis anymore |
| Q36326349 | Protein phosphatase PHLPP induces cell apoptosis and exerts anticancer activity by inhibiting Survivin phosphorylation and nuclear export in gallbladder cancer |
| Q64061300 | Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer |
| Q35512805 | Qualitative Network Modeling of the Myc-p53 Control System of Cell Proliferation and Differentiation |
| Q39274129 | R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway |
| Q56765170 | RETRACTED: Turning up the heat in the fat cell |
| Q27009016 | Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications |
| Q42535880 | Self-renewal versus transformation: Fbxw7 deletion leads to stem cell activation and leukemogenesis |
| Q33687282 | Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. |
| Q46876173 | T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus |
| Q35571372 | Targeting the PI3K-Akt pathway in human cancer: rationale and promise |
| Q35640098 | Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs |
| Q36536993 | The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer |
| Q38111449 | Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma |
| Q58609591 | Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network |
| Q24292946 | Ubiquitination regulates PTEN nuclear import and tumor suppression |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
Search more.